Participation in the review does not necessarily consti- tute endorsement of the content of this report by the above individuals, or the organization or institution they represent. Gavin J Becker, MD, FRACP David C Wheeler, MD, FRCP Work Group Co-Chairs acknowledgments http://www.kidney-international.org & 2012 KDIGO References 1. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1 S290. 2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1 S266. 3. Levey AS, Atkins R, Coresh J et al. Chronic kidney disease as a global public health problem: approaches and initiatives a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72: 247 259. 4. Levin NW, Kotanko P, Eckardt KU et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2010; 77: 273 284. 5. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53: 860 866. 6. Heerspink HJ, Ninomiya T, Zoungas S et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009 1015. 7. KDIGO GN Work Group. KDIGO clinical practice guideline for glome- rulonephritis. Kidney inter, Suppl 2012; 2: 139 274. 8. Magee LA, Abalos E, von Dadelszen P et al. Control of hypertension in pregnancy. Curr Hypertens Rep 2009; 11: 429 436. 9. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treat- ment of High Blood Pressure. Hypertension 2003; 42: 1206 1252. 10. 